Drug Trial Radar · NCT04017338
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 6, 2018
Primary completion
Dec 31, 2020
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Jordan FeldAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Health Network, Toronto
- First posted
- Jul 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The success of transplantation is significantly hindered by the lack of sufficient number of available donors. Many potential donor organs cannot be utilized in clinical transplantation because donors have chronic viral infections such as hepatitis C (HCV) infection. This study will test the possibility of safely transplanting organs from HCV-infected donors into HCV-uninfected recipients. Prior to transplantation, recipients will receive an initial dose of highly effective antiviral prophylaxis using approved direct-acting antivirals (DAAs) Glecaprevir/Pibrentasvir (G/P) and they will also receive ezetimibe, a cholesterol-lowering medication that also blocks entry of HCV into liver cells. They will then receive daily dosing of the same medications for 7 days after transplant. The aim of the study is to show that transplantation of organs from HCV+ donors is safe in the era of DAAs. The investigators hypothesize that rates of HCV transmission to recipients will be prevented by the use of DAA prophylaxis and any HCV transmission that does occur will be readily treatable and curable. If successful, the knowledge from this study can have a large impact to patients with end stage organ diseases by providing a large novel source of donors for organ transplantations.
Conditions
- Lung Transplant Infection
- Heart Transplant Infection
- Kidney Transplant Infection
- Kidney Pancreas Infection
- Hepatitis C
Interventions
Glecaprevir 300 MG / Pibrentasvir 120 MG Oral TabletDrug
A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
Ezetimibe 10Mg Oral TabletDrug
A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
Ex Vivo Lung PerfusionDevice
A technology that allows for the assessment and treatment of lungs prior to transplant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-transplant Survival [Safety]Time frame: 6 months
- Incidence of HCV transmission [Safety]Time frame: 6 months
- Incidence of treatment-emergent adverse events [Safety and Tolerability]Time frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Health Network Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.